|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Advaxis, Inc. Continues Collaboration with Former National Cancer Institute Vaccines Chief in New Position as Director of the Georgia Health Sciences University Cancer Center
3/20/2012 7:19:51 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced it will continue its collaboration with Dr. Samir N. Khleif, the former Chief of the Vaccines Section at the National Cancer Institute (NCI), at his new position of Director of the Georgia Health Sciences University Cancer Center at Augusta, Georgia. While at NCI, Dr. Khleif designed many of the early cancer vaccine clinical trials targeting specific genetic changes in cancer that might enable the immune system to attack cancer cells, and identified mechanisms used by tumors to defend against immune attack. The Khleif lab will continue to elaborate the molecular immunologic mechanisms by which live, attenuated strains of Listeria monocytogenes can effect therapeutic changes in cancer and other diseases.
|
|
|
|
|
|
|
|
|
|
|